According to US Food & Drug Administration (FDA) statistics, only around one in every ten new medicinal products that progress to clinical trials ever reaches the registration stage, with approximately half of all drug failures attributed to problems with efficacy, bioavailability, toxicity or clinical safety, which were not anticipated following preclinical studies. 1 The statistics also indicate that the number of new drug submissions has fallen over the last few years. 2 Furthermore, although actual market withdrawals are rare, adverse drug events have more than doubled since 1998, and around 20% of successfully marketed drugs have their later use restricted by so-called 'black-box' labelling on the basis of human data gathered during post-marketing surveillance. [3] [4] [5] The cost of this level of attrition can only truly be appreciated, if we consider that there is only an 8% chance that a drug that has been in development for an average of 10 years will ever be marketed, and an even lower chance that this drug will be a blockbuster drug.
The question then remains as to why, despite considerable innovation in recombinant DNA technology, cell culture techniques, in silico and biophysical methodology, and a number of other enabling technologies, are drug attrition rates so high? One contributory factor is that the lead selection process removes a disproportionately high number of potentially useful lead candidates, because the screens are too reductionist. Added to this is the possibility that new drug entities and biopharmaceuticals that appear to be effective and safe according to animal studies, are later shown not to be efficacious and/or safe in patients in general, or in specific patients. Conversely, many potentially useful candidates may be dropped on the basis of the outcomes of animal studies, because they do not appear to have a suitable therapeutic window, even though this may not be the case in humans. A final possibility is the fact that the pharmaceutical market has steadily changed over recent decades, with pharmaceutical companies investing considerable efforts in the identification of new drug targets and therapeutic agents which have inherently less well understood mechanisms, or which target increasingly complex diseases, so that the existing evaluation paradigms are not appropriate.
A Time to Critically Evaluate All Preclinical Methods?
Traditionally, human physiology and diseases have been modelled by taking only a single factor, or a handful of factors, into consideration. This approach has resulted in transgenic animals that express a single human gene, being considered as valid models, without a sufficient understanding of the functional equivalence of the expression product in the test species and in humans or, indeed, sufficient monitoring of other physiological and biochemical factors that might determine the role of the gene product as a drug target or effector. Equally, this reductionist outlook has resulted in a plethora of cell-based assays that attempt to explain human biology and drug action in a way that can only indicate whether a particular substance affects one or a few cellular events, with no real indication as to whether they have any relevance to activity in the in vivo situation. Thus, the traditional drug development paradigms give very narrow views of drug action, with often uncertain translation to the clinic. For instance, these paradigms often do not assist with the prediction of multiple organ toxicity that is linked to around 10% of all drug failures, or with the estimation of the effects of longer term or repeated patient exposure, such as hypersensitivity, immunogenicity, bioretention, genetic or organ damage, or metabolic impairment. Reviewing the performance of individual methods in the light of clinical outcomes plays an important role in this respect, as it can help to determine the fitness of the methods for patient assessment, the success of extrapolation of the results to the clinical situation, and the relevant applicability domains. In this sense, the process is akin to that the retrospective (or weight-of-evidence) validation of alternative methods, except that it is perhaps more flexible, is also applicable to individual methods and approaches, and is more suited to overall drug evaluation than simply to safety testing.
The need for integrated drug development and testing strategies that focus on gaining an overall view of drug action within the human body, is now widely acknowledged. In this sense, perhaps the assessment of mitochondrial toxicity can provide some valuable clues, since it is clear that effects on ATLA 37, 335-339, 2009 335 Editorial 21st Century Drug Development: Advances, Opportunities and Challenges specific mitochondrial pathways can be linked to increased toxicity toward selected and/or multiple organs. Susana Pereira and her co-authors describe the various pathways which might be affected. 6 What remains to be established is whether there is a clear relationship between the disruption of a particular mitchondrial pathway and toxicity to specific organs. In terms of the predictive value of animal experiments, the accuracy with which patient safety is estimated varies, depending on the target organ for toxicity, with the prediction of cardiovascular, haematopoietic and gastrointestinal toxicity being considerably higher than that of toxicity to the liver, skin and nervous system. 7 As eluded to by Robert Smith in his article on neurotoxicity assessment, 8 mapping cognitive and behavioural changes of relevance to humans in animal models is no simple matter. The plasticity of the adolescent human brain, structural and functional differences between test species and humans, and the way in which neurotransmission influences behaviour, confound the extrapolation of experimental results to patients in the clinic. This is perhaps best illustrated by the Seroxat controversy, which illustrates that, not only can some drugs, such as this selective serotonin reuptake inhibitor, cause dependency, but that withdrawal symptoms may have very different presentations in animals and in selected patients.
It is clear that most toxic drugs belong to a few distinct therapeutic or mechanistic classes of drugs -such as the COX-2 inhibitors, Vioxx and Bextra, drugs that target immune function (e.g. Seldane), and narcotics (e.g. Fentanyl and morphine). In view of this, a thorough examination of the mechanisms of the toxicity of these drugs might be of benefit, if it could guide preclinical studies and the development of non-animal models based on the use of human cells and tissues.
Accounting for Patient Differences
A single animal model can, at best, hope to capture elements of the drug-related events in a subpopulation of patients, since there is no such thing as an average human response. Furthermore, companies such as Abbott and AstraZeneca recognise that it is often the patients that fall outside the normal response range that prove most informative for drug development and clinical management. This then throws open the question as to whether an animal model of the average patient is ever a reasonable founding premise for embarking upon model development. Accounting for human variation by using animal models is logistically difficult, and would raise considerable animal welfare concerns, since it would almost certainly require the use of multiple strains or species, even more so than is already required for the assessment of some products, and in particular, biopharmaceuticals. A more reasonable starting point is to use in vitro and in silico approaches or, preferably, ex vivo cells and tissues from representative patients. Nevertheless, the use of these approaches to map the complex interplay between functional body systems, and thus estimate patient differences, is still problematic, since they do not capture a holistic view of human physiology or drug action.
Human Systems Biology: The Prospects and Challenges
Systems biology entails the compilation of a view of human physiology, disease or response to a therapy, based on a consideration of cellular function at the genetic, protein and metabolic levels. In order for systems biology to inform the development of human medicines, it must incorporate information from studies on human organelles, cells, tissues and organs, that are able to take into account key variations within the patient population. If this can be achieved, human systems biology is undoubtedly the way forward. In vitro models, in which cells representative of different organ or sub-organoid structures are assembled into 2-D and 3-D organotypic models or are connected by a microfluidics system, might fare well in this respect, especially if cellular interactions within key organs and sub-organoid structures were represented. Indeed, sophisticated multiple cell and tissue models, such as the Integrated Discrete Multiple Organ Co-culture system described by Albert Li in this issue of ATLA, 9 are already showing considerable promise, as they appear to be more indicative of events such as multiple organ toxicity than are simple cell-based assays.
Systems biology is made possible by a number of technologies. These include: automated sampling; microfluidics-, microplate-and compact disc (CD)engrafted technologies; high-content screening; and sensitive biophysical and biochemical analysis platforms. In silico data collation, mining and analysis, are also vital aspects of systems biology. It is evident that these in silico tools are relatively effective for the pre-selection and rational design of small chemical drugs. However, when it comes to guiding the selection of candidate biotherapeutics, such as recombinant proteins, nucleic acid derivatives or stem-cell therapeutics, or determining the safety, bioavailability or, indeed, the efficacy of these products, many of these in silico tools are still very much in their infancy. This is because these products often exhibit heterogeneity as a consequence of varied post-translational protein folding, processing and degradation, aggregation, or physical damage. Difficulties in the use of in sil-ico methods for the testing of nanomaterials have also arisen, due to the presence of heterogeneous nanoparticles within a sample. All of these factors influence bioavailability, reactivity, toxicity, efficacy and stability -and the variability which most existing in silico models have difficulty accounting for. Therefore, in terms of in silico approaches, it is clear that the structural and functional diversity of 'new-era' therapeutics presents a considerable challenge.
Hence, there is an urgent need for a new approach to drug development, one which involves the targeted use of new and advanced technologies that are based on defined cell systems, either as stand-alone alternatives to animal studies, as tools to assist in the extrapolation of animal data to humans, or to facilitate the conduct of clinical trials or inform clinical management. In 2004, the FDA produced a report 1 that suggested that the fall in drug development returns was due largely to the failure to incorporate information from new technologies, such as genomics, proteomics and bioinformatics platforms, to detect safety issues that cannot be identified by the more traditional animal-based methods. At the time, systems biology-based approaches were very much in their developmental stages. More recently, biomarkers have been qualified to assist with the diagnosis and management of diseases such as cancer, diabetes and liver disease. The drive to improve clinical efficacy has resulted in a great deal of effort to also qualify biomarkers to guide treatment options and to help to identify patient demographics that would benefit from, or display unacceptable levels of toxic effects as a result of treatment with, a therapeutic. These socalled theranostics show enormous promise within the clinical setting.
It remains necessary to determine the role of such biomarkers in guiding the development of alternatives suited for the preclinical evaluation of therapeutic agents. The Innovative Medicines Initiative in the EU (http://imi.europa.eu/index_ en.html) and the US Critical Path Initiative (http://www.fda.gov/ScienceResearch/SpecialTopic s/CriticalPathInitiative/default.htm) are both examining the prospects of developing and qualifying tools, including biomarkers, that can reduce research bottlenecks in estimating drug efficacy and safety. However, the employment of preclinical biomarkers for efficacy is likely to be favoured over that of safety biomarkers, since the use of surrogate toxicological endpoints based on the measurement of one or more biomarker is viewed with considerable discomfort by regulators, who are of the view that there is no surrogate for safety. There is a general idea that, if biomarkers which are qualified for clinical use are subsequently incorporated into new preclinical models, then this can increase the confidence with which the preclinical data can be extrapolated to the clinic.
However, one important consideration to bear in mind is that there is some uncertainty as to whether the expression of a single biomarker can instigate, or indeed influence, a number of physiological and gene-related events. Another significant problem is standardising and validating these new technologies, to ensure that the quality of the data and the data analysis is suitable for the evaluation of efficacy and safety. Despite these barriers, there has been recent acceptance by the European Medicines Agency (EMEA) and FDA of seven urinary biomarkers identified by the Critical Path Institute's Predictive Safety Testing Consortium (PSTC) as tools to improve the predictivity of renal safety during preclinical studies in rats. This work has also refined the way the EMEA, the FDA and the industry manage the qualification of safety biomarkers, since these regulatory agencies are now willing to consider biomarker qualification by a step-wise and progressive approach. This will, over time, facilitate data addition and the wider application of the biomarkers over and above their original specification for use.
Future Medicines, New Challenges
A recent survey 10 indicates that over half of the drugs on the market target one of only four key gene families, namely seven-transmembrane (7TM) receptors, nuclear receptors, ligand-gated ion channels, and voltage-gated ion channels. In an attempt to expand on this basic repertoire of targets, pharmaceutical companies have turned to targets identified by genomic analysis. As a result, a number of biopharmaceuticals, in particular, target human disease-specific pathways. This has resulted in a situation where biopharmaceuticals now comprise around 40% of all the drugs in the development pipeline. These products interact with substantially fewer well-defined or novel targets. 11 Often, both the target and the biopharmaceutical are less amenable to structure-activity studies and require significantly different evaluation approaches to those used in the development of small-molecule drugs. Among the most common reasons for withdrawal of biopharmaceuticals are loss of efficacy due to the generation of antibodies toward a product, risk of fatal infections due to immunosuppression, and cytokine release syndrome. This is in contrast to the situation with many small drug entities, where the main reason for their withdrawal is their evident hepatotoxicity. The potential for effects on the diverse array of cells and tissues that form the immune system make it extremely difficult to accurately gauge whether a biopharmaceutical will elicit an immune response, and the nature that it will take. Furthermore, it is clear that in some therapeutic areas, such as oncology, where biopharmaceuticals are increasingly used, these types of problems have been identified as being some of the main reasons behind the 82% attrition rate for 974 anticancer agents entering into clinical development between January 1995 and September 2007. 5 Emanuela Corsini and Erwin Roggen, in their article featured in this issue of ATLA, 12 highlight many of the limitations of blood and blood-cell based assays, in terms of predicting immunotoxicity. However, by exploiting the potential of dendritic cells, T-cells and B-cells to undergo in vitro activation and proliferation, groups within the USA and Germany have been able to develop models that capture responses to biologicals and chemicals, and that can assist with the identification of suitable vaccines and chemical and biological therapeutic candidates. 13, 14 The importance of developing such models is highlighted by the fact that: a) most studies in non-human species simply cannot capture human-relevant immunological effects; and b) the reliance on non-human primates has, perhaps erroneously, and certainly regrettably, increased, as evidenced by the recent upturn in primate experimentation.
Ironically, it is accepted that no animal is ideally suited for such studies. The justification for the continued use of animals is therefore based on a 'better than nothing' principle. This is not acceptable, both in terms of its implications for human health and for animal welfare. Biopharmaceuticals, nanomaterials and stem-cell and gene therapies, have not appeared overnight. There has been ample opportunity to consider the testing needs for these products and to identify approaches that are both scientifically sound and ethically acceptable. This serves as an important reminder of the value of horizon scanning to preempt future uses of laboratory species. Had the testing needs been considered from the date of conception of such therapeutic modalities, perhaps alternative approaches would be now available and thus our current reliance on animal studies would have been minimalised.
Concluding Remarks
There is a tacit acceptance that the use of animals for the development and testing of new human or veterinary medical products is scientifically and ethically justifiable, in so far as such experimentation is able to add value to the evaluation of new and existing products. It is on these grounds that we face the first stumbling block, in that, not only have many animal experiments failed to deliver on highly publicised promises to improve healthcare, but also they play a considerable role in the causation of the unacceptably-high current drug attrition rates. A number of key pharmaceuticallydriven initiatives have been established to assess and address the reasons for drug attrition. Among the forerunners are the EU Innovative Medicines Initiative and the US Critical Path Initiative. The general consensus is that a more flexible and multi-disciplinary approach to drug discovery and development is needed. Consequently, the demarcation between basic and applied science is being constantly eroded, such that the formal validation of a select number of test methods is unlikely to be the way forward. Instead, there has to be a shift in thinking that takes on board the limitations of all the available methods and looks positively at future drug development needs, as well as at the problem of drug attrition. This requires that all models are critically evaluated by using patient outcomes as the "gold standard" rather than data of limited value from animal models. 
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